|
||
Flu-Amp Uses |
||
UNASYN is indicated for the treatment of infections due to susceptible strains of the designated
microorganisms in the conditions listed below.
Skin and Skin Structure Infections caused by beta-lactamase producing strains of
Staphylococcus aureus, Escherichia coli, Klebsiella spp. (including K. pneumoniae), Proteus
mirabilis, Bacteroides fragilis, Enterobacter spp., and Acinetobacter calcoaceticus.
Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli,
Klebsiella spp. (including K. pneumoniae), Bacteroides spp. (including B. fragilis), and
Enterobacter spp.
Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli, and
Bacteroides spp. (including B. fragilis).
Efficacy for this organism in this organ system was studied in fewer than 10 infections.
While UNASYN is indicated only for the conditions listed above, infections caused by
Ampicillin (Flu-Amp)-susceptible organisms are also amenable to treatment with UNASYN due to its
Ampicillin (Flu-Amp) content. Therefore, mixed infections caused by Ampicillin (Flu-Amp)-susceptible organisms and
beta-lactamase producing organisms susceptible to UNASYN should not require the addition of
another antibiotic.
Appropriate culture and susceptibility tests should be performed before treatment in order to
isolate and identify the organisms causing infection and to determine their susceptibility to
UNASYN.
Therapy may be instituted prior to obtaining the results from bacteriological and susceptibility
studies, when there is reason to believe the infection may involve any of the beta-lactamase
producing organisms listed above in the indicated organ systems. Once the results are known,
therapy should be adjusted if appropriate.
To reduce the development of drug-resistant bacteria and maintain effectiveness of UNASYN
and other antibacterial drugs, UNASYN should be used only to treat or prevent infections that are
proven or strongly suspected to be caused by susceptible bacteria. When culture and
susceptibility information are available, they should be considered in selecting or modifying
antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns
may contribute to the empiric selection of therapy.
Probenecid decreases the renal tubular secretion of Ampicillin (Flu-Amp) and
sulbactam. Concurrent use of probenecid with UNASYN may result in increased and prolonged
blood levels of Ampicillin (Flu-Amp) and sulbactam. The concurrent administration of allopurinol and
Ampicillin (Flu-Amp) increases substantially the incidence of rashes in patients receiving both drugs as
compared to patients receiving Ampicillin (Flu-Amp) alone. It is not known whether this potentiation of
Ampicillin (Flu-Amp) rashes is due to allopurinol or the hyperuricemia present in these patients. There are no
data with UNASYN and allopurinol administered concurrently. UNASYN and aminoglycosides
should not be reconstituted together due to the in vitro inactivation of aminoglycosides by the
Ampicillin (Flu-Amp) component of UNASYN.
Adult Patients: UNASYN is generally well tolerated. The following adverse reactions have been
reported.
Local Adverse Reactions
Pain at IM injection site – 16%
Pain at IV injection site – 3%
Thrombophlebitis – 3%
Systemic Adverse Reactions
The most frequently reported adverse reactions were diarrhea in 3% of the patients and rash in
less than 2% of the patients.
Additional systemic reactions reported in less than 1% of the patients were: itching, nausea,
vomiting, candidiasis, fatigue, malaise, headache, chest pain, flatulence, abdominal distension,
glossitis, urine retention, dysuria, edema, facial swelling, erythema, chills, tightness in throat,
substernal pain, epistaxis and mucosal bleeding.
Pediatric Patients: Available safety data for pediatric patients treated with UNASYN
demonstrate a similar adverse events profile to those observed in adult patients. Additionally,
atypical lymphocytosis has been observed in one pediatric patient receiving UNASYN.
Adverse Laboratory Changes
Adverse laboratory changes without regard to drug relationship that were reported during clinical
trials were:
Hepatic: Increased AST (SGOT), ALT (SGPT), alkaline phosphatase, and LDH.
Hematologic: Decreased hemoglobin, hematocrit, RBC, WBC, neutrophils, lymphocytes,
platelets and increased lymphocytes, monocytes, basophils, eosinophils, and platelets.
Blood Chemistry: Decreased serum albumin and total proteins.
Renal: Increased BUN and creatinine.
Urinalysis: Presence of RBC
This medicine is not given to individuals who have previous Penicillin or cephalosporin allergy and should be used with caution in individuals with histories of significant allergies and/or asthma.
Ampicillin/Flucloxacillin in United Kingdom.
Ampicillin trihydrate/flucloxacillin sodium in United Kingdom.
List of Flu-Amp substitutes (brand and generic names) | Sort by popularity |
Unit description / dosage (Manufacturer) | Price, USD |
Ampicillin trihydrate/flucloxacillin sodium | |
Ampicillin/Flucloxacillin (Malta, United Kingdom) | |
Ampiflux (Egypt) | |
Co-Fluampicil (Malta, United Kingdom) | |
Capsule; Oral; Ampicillin Trihydrate 250 mg; Flucloxacillin Sodium 250 mg | |
Syrup; Oral; Ampicillin Trihydrate 125 mg; Flucloxacillin Sodium 125 mg / 5 ml | |
Co-Fluampicil Injection | |
Injectable; Injection; Ampicillin Sodium 250 mg; Flucloxacillin Sodium 250 mg | |
Magnapen (Peru, United Kingdom) | |
Capsule; Oral; Ampicillin Trihydrate 250 mg; Flucloxacillin Sodium 250 mg (Cp pharmaceuticals) | |
Syrup; Oral; Ampicillin Trihydrate 125 mg; Flucloxacillin Sodium 125 mg / 5 ml (Cp pharmaceuticals) | |
Magnapen Injection | |
Injectable; Injection; Ampicillin Sodium 250 mg; Flucloxacillin Sodium 250 mg |
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|